Video via Wongel Zelalem

Tonix will test its monkeypox vaccine in Kenya next year, and no eyes on accelerated path at FDA

The study of Tonix Pharmaceuticals’ live virus vaccine will occur at Kenya Medical Research Institute, or KEMRI, in the East African country, the partners said Thursday. While Kenya has no reported cases of the virus that leads to painful lesions, the country is close to the Democratic Republic of the Congo, which had 163 cases as of July 27, according to a CDC tracker.

…

Tonix has been working on monkeypox and smallpox for close to a decade, Lederman said. The company’s vaccine, dubbed TNX-801, is traced back to a research collaboration with the Department of Cell Biology at the University of Alberta.

Related:

WHO Issues Monkeypox Advisory to Kenya

WHO also advised that members of the public should avoid skin contact to avoid the spread of the disease in the event that the first case is reported in the country.

“Avoid skin-to-skin, face-to-face, mouth-to-skin contact including sexual contact. Clean hands, objects, surfaces, bedding, towels, and clothes regularly

“Wear a mask if you can’t avoid close contact and when handling bedding, towels, and clothes,” the WHO advised.

Last month, Health Principal Secretary Susan Mochache, assured the country that they were on high alert over the disease, especially at the country’s entry points.

She stated that no case had been reported in the country urging Kenyans to be vigilant of the symptoms.